Many investors have made tons of money by investing in small-cap biotech stocks, especially those that are still relatively obscure. One potential investment candidate that's slipped under the radar due to the coronavirus pandemic is Omeros Corporation (NASDAQ: OMER). A biotech company that first went public in 2009, Omeros has already received U.S. Food and Drug Administration (FDA) approval for an earlier candidate.
With a couple of major catalysts coming up this year, could this company make early investors a fortune? Let's take a deeper look at what's going on with Omeros and whether it's worth a spot in your portfolio.
Image source: Getty Images.